Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting
Rapport Therapeutics announced it will present new 8-week follow-up data from its Phase 2a trial of RAP-219, a novel targeted treatment for focal onset seizures, at the 2026 American Academy of Neurology Annual Meeting. RAP-219 specifically modulates the TARP-γ8 AMPA receptor subunit, potentially offering improved efficacy and tolerability for neur…